These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11713406)

  • 1. Treatment of an orchiectomized patient with hormone-refractory prostate cancer with LH-RH agonists.
    Damyanov C; Tzingilev B; Tabakov V
    Eur Urol; 2001 Oct; 40(4):474-6; discussion 477. PubMed ID: 11713406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
    Krongrad A; Brady J; Rodriguez RJ
    South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M; de Reijke TM; Zurlo A; Collette L
    Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
    [No Abstract]   [Full Text] [Related]  

  • 5. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer.
    Nishiyama T; Terunuma M
    Int J Urol; 1998 Jan; 5(1):44-7. PubMed ID: 9535600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.
    Liu SV; Schally AV; Hawes D; Xiong S; Fazli L; Gleave M; Cai J; Groshen S; Brands F; Engel J; Pinski J
    Clin Cancer Res; 2010 Sep; 16(18):4675-80. PubMed ID: 20670943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
    Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
    Koga H; Naito S
    Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics, effects, side effects of the LH-RH agonist].
    Miyanaga N; Akaza H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
    [No Abstract]   [Full Text] [Related]  

  • 13. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R; Norum J; Due J
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
    Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
    N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
    Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
    Cancer; 2005 Apr; 103(8):1615-24. PubMed ID: 15742331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
    Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
    J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of LH_RH analogs in the treatment of cancer of the prostate. A report of the conference organized by ICI_Pharma Laboratories (part 1)].
    Prog Urol; 1991 Feb; 1(1):165-8. PubMed ID: 1364642
    [No Abstract]   [Full Text] [Related]  

  • 19. Reinduction of hormone sensitivity to goserelin following chemotherapy with vinorelbine in castration-resistant prostate cancer.
    Grenader T; Goldberg A
    ScientificWorldJournal; 2010 Sep; 10():1814-7. PubMed ID: 20852824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.